ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

ZP9830

A development code.

Its studies are mostly in Psoriasis, led by Zealand Pharma.

Furthest: phase 1, since Nov 7, 20242 company-led studies, 2 open or runningNext primary completion: Apr 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Zealand Pharma22 open or runningphase 1since Nov 7, 2024Nov 7, 2024Apr 2027phase 1 · NCT07733089

Also a collaborator on its studies: ICON Clinical Research.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 7, 2024First study: phase 1 study in Healthy VolunteersFirst studyNCT06682975 · 124 planned · Netherlands
  2. Jun 15, 2026Phase 1 study in Plaque PsoriasisNCT07733089 · 32 planned · Netherlands

Ahead

  1. Apr 2027Primary completion: phase 1 study in Plaque PsoriasisNCT07733089

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07733089Plaque Psoriasis · Netherlands1RecruitingApr 202732
NCT06682975Healthy Volunteers · Netherlands1RecruitingAug 2026124

How it is read

Names in the registry

  • “ZP9830”, 2 entries

Codes read as this program: ZP9830.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.